within Pharmacolibrary.Drugs.ATC.L;

model L01XG03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.58,
    Cl             = 0.031000000000000003,
    adminDuration  = 600,
    adminMass      = 0.004,
    adminCount     = 1,
    Vd             = 0.543,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.006833333333333333,
    Tlag           = 24.599999999999998
  );

  annotation(Documentation(
    info ="<html><body><p>Ixazomib is an oral proteasome inhibitor indicated for the treatment of multiple myeloma in combination with lenalidomide and dexamethasone in patients who have received at least one prior therapy. It is approved and currently used for this indication.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetics in adult patients with relapsed/refractory multiple myeloma; both sexes; typical age range 40-80 years. Parameters are representative of standard oral administration and are based on published studies.</p><h4>References</h4><ol><li>Neeraj Gupta, Michael J Hanley, Karthik Venkatakrishnan, Raymond Perez, Robin E Norris, John Nemunaitis, Huyuan Yang, Mark G Qian, Gerald Falchook, Richard Labotka, Siqing Fu,Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment.,British journal of clinical pharmacology,2016<a href='https://pubmed.ncbi.nlm.nih.gov/27121262/'>https://pubmed.ncbi.nlm.nih.gov/27121262/</a></li><li>Matt Shirley,Ixazomib: First Global Approval.,Drugs,2016<a href='https://pubmed.ncbi.nlm.nih.gov/26846321/'>https://pubmed.ncbi.nlm.nih.gov/26846321/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L01XG03;
